Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03495921
Title Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)
Acronym VITA
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gradalis, Inc.
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA

Facility Status City State Zip Country Details
Arkansas Children's Hospital Little Rock Arkansas 72202 United States Details
Southern California Permanente Medical Group Los Angeles California 90027 United States Details
Mayo Clinic Florida Jacksonville Florida 32224 United States Details
Nicklaus Children's Hospital Miami Florida 33155 United States Details
Dana-Farber/Boston Children's Cancer and Blood Disorders Boston Massachusetts 02215 United States Details
Washington University Siteman Cancer Center Saint Louis Missouri 63110 United States Details
Nebraska Methodist Hospital Omaha Nebraska 68114 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Duke Children's Hospital and Health Center; Duke Cancer Institute Durham North Carolina 27710 United States Details
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Texas Oncology - Pediatrics Dallas Texas 75230 United States Details
Cook Children's Medical Center Fort Worth Texas 76104 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field